Novel Therapies in Cancer: Trials and Tribulations.

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2024-09-03 DOI:10.1158/1078-0432.CCR-24-1127

Saiama N Waqar, Ramaswamy Govindan

引用次数: 0

Abstract

Clinical trials are the backbone for advancing therapeutic options for patients diagnosed with cancer. Yet only 7.1% of patients with cancer participate in clinical trials in the United States. In this article, we review some of the reasons for poor accrual and discuss potential solutions. See related article by van Berge Henegouwen et al., p. 3937.

查看原文本刊更多论文

癌症新疗法：试验与磨难。

临床试验是推进癌症患者治疗方案的支柱。然而，在美国只有 7.1% 的癌症患者参加了临床试验。我们回顾了累积率低的一些原因，并讨论了潜在的解决方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.

文献相关原料

公司名称	产品信息	采购帮参考价格